- Home
- TNYA vs KOD Comparison
TNYA vs KOD Comparison
Compare TNYA & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNYA
- KOD
- Stock Information
- Founded
- TNYA 2016
- KOD 2009
- Country
- TNYA United States
- KOD United States
- Employees
- TNYA N/A
- KOD N/A
- Industry
- TNYA Medicinal Chemicals and Botanical Products
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TNYA Health Care
- KOD Health Care
- Exchange
- TNYA Nasdaq
- KOD Nasdaq
- Market Cap
- TNYA 189.1M
- KOD 198.4M
- IPO Year
- TNYA 2021
- KOD 2018
- Fundamental
- Price
- TNYA $1.29
- KOD $9.68
- Analyst Decision
- TNYA Strong Buy
- KOD Hold
- Analyst Count
- TNYA 5
- KOD 4
- Target Price
- TNYA $8.60
- KOD $11.75
- AVG Volume (30 Days)
- TNYA 3.0M
- KOD 484.4K
- Earning Date
- TNYA 11-05-2025
- KOD 11-13-2025
- Dividend Yield
- TNYA N/A
- KOD N/A
- EPS Growth
- TNYA N/A
- KOD N/A
- EPS
- TNYA N/A
- KOD N/A
- Revenue
- TNYA N/A
- KOD N/A
- Revenue This Year
- TNYA N/A
- KOD N/A
- Revenue Next Year
- TNYA N/A
- KOD N/A
- P/E Ratio
- TNYA N/A
- KOD N/A
- Revenue Growth
- TNYA N/A
- KOD N/A
- 52 Week Low
- TNYA $0.36
- KOD $1.92
- 52 Week High
- TNYA $4.01
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- TNYA 61.07
- KOD 55.68
- Support Level
- TNYA $1.15
- KOD $9.10
- Resistance Level
- TNYA $1.43
- KOD $9.93
- Average True Range (ATR)
- TNYA 0.09
- KOD 0.73
- MACD
- TNYA -0.01
- KOD -0.12
- Stochastic Oscillator
- TNYA 63.13
- KOD 60.52
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.